Federal Reserve chair Kevin Warsh said economic growth has picked up, but that does not mean it is triggering inf.

Jiangsu Hengrui Medicine Co., Ltd said its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd has received an approval notice from the National Medical Products Administration to begin clinical trials of HRS-2189 tablets and will start trials shortly. HRS-2189 is a novel KAT6 inhibitor that downregulates oncogene expression by inhibiting histone lysine acetylation and is being developed for advanced malignant tumors. No other KAT6-targeting drug is currently approved domestically or abroad. R&D investment in the HRS-2189 program to date totals about 55.3 mln yuan.

美國財長貝森特：特朗普經濟議程的很大一部分已經落地，比如減稅。